All articles

Mounjaro Patches: Are They Real, Safe, Or Effective For Weight Loss?

Mounjaro Patches: Are They Real, Safe, Or Effective For Weight Loss?


Written by:

Dr. Zoë Lees (PhD)

Medically reviewed by:

Dr. Sophie Dix (BSc, PhD)

Published:

4 August 2026

Reading time: 11 minutes
Mounjaro Patches: Are They Real, Safe, Or Effective For Weight Loss?

Weight loss medications are becoming more and more popular in the UK, but it can be hard to know what works, what you can trust, and what's just clever marketing. And while injectable and oral medications are well established for their weight loss benefits, you may have also come across weight loss patches in your search for support. But like others online, you might be wondering: are weight loss patches real?

The short answer is that they do exist. But while weight loss patches are a real product and often suggested as a natural alternative to Mounjaro or Wegovy, they’re not the same as licensed, prescription weight loss medications that contain glucagon-like peptide-1 (GLP-1) receptor agonists. And they’re not made by either of these well-known brands.

In this guide, our experts will explain what so-called GLP-1 patches do, how they work and the science behind them, as well as the risks and side effects.

Article Summary:

  • Weight loss patches are often promoted as an alternative to prescription weight loss injections like Mounjaro and Wegovy. However, they don’t contain GLP-1 receptor agonists and don’t work in the same way. Instead, they usually contain natural extracts or herbal ingredients.
  • Mounjaro is only available as an injectable weight loss treatment, not a patch. It must be prescribed by a qualified clinician following a consultation to review your health.
  • Weight loss patches are not approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) or licensed as medicines in the UK, which means they’re not regulated like GLP-1 medications.

Do Mounjaro patches exist and are they available in the UK?

First things first: there’s no such thing as a Mounjaro patch.

Mounjaro is a prescription medication that's only available as a self-injectable pen, which is designed to be used once a week to help support weight loss. Mounjaro contains the active ingredient tirzepatide, a dual GIP/GLP-1 receptor agonist which was originally used to treat type 2 diabetes. It’s now used for weight management, and works by reducing hunger, keeping you fuller for longer, regulating blood sugar and silencing food noise. [1]

What are weight loss patches?

While Mounjaro patches don’t exist, other weight loss patches do. They’re available as over-the-counter (OTC) products from different brands.

These adhesive patches stick onto your skin much like a nicotine patch or hormone replacement therapy (HRT) patch. They claim to help you lose weight by delivering ingredients through the skin, officially known as transdermal delivery.

In the UK, no weight loss patches are approved by the MHRA or licensed as medicines, so they’re not regulated in the same way as prescription weight loss injections like Wegovy or Mounjaro. [2]

GLP-1 patches: The hype vs the reality

As a treatment option, weight loss patches sound enticing. No needles, no pills, no medical approval needed, and they’re usually cheaper too. So it’s no wonder they get plenty of hype on social media platforms.

But before we delve into how they work and the research behind them, there’s an important caveat: weight loss patches are not GLP-1 patches.

They don’t contain GLP-1 medications like semaglutide and tirzepatide, the proven active ingredients in Wegovy and Mounjaro, respectively. Any products named ‘GLP-1 patches’ are misleading, and shouldn’t be trusted.

So if you’re considering trying a weight loss patch, remember it can’t be compared to prescription weight loss treatments. They are very different approaches, contain different active ingredients and work in different ways.

How do weight loss patches work?

Weight loss patches come in the form of transdermal patches that stick to your skin. In general, they should be applied to a clean, dry area of skin and are usually worn for around 8 hours, though it varies widely depending on the brand you choose. [3]

The adhesive patches are designed to release their ingredients so that they pass through the skin and into the bloodstream, usually with claims that they help suppress your appetite throughout the day.

This method of delivery is why Mounjaro patches aren't currently possible. The active ingredient, tirzepatide, is a large peptide that would either be broken down or poorly absorbed if it was applied as a patch, making it ineffective. It has to be delivered via a subcutaneous injection instead, which means it goes into the fatty tissue just under the skin. This is to make sure it bypasses the skin barrier and gets into the bloodstream. [4]

Do weight loss patches contain GLP-1 medications?

Unlike Wegovy or Mounjaro, weight loss patches don't contain GLP-1 medications. They usually contain a combination of herbal supplements, stimulants and metabolism-supporting ingredients, such as caffeine, green tea extract, berberine, seaweed, garcinia cambogia (a tropical fruit), or vitamin blends.

These ingredients are chosen for their ability to pass through the skin and into the bloodstream, whereas GLP-1 medications like tirzepatide and semaglutide can’t be absorbed this way.

Are weight loss patches effective?

Because weight loss patches aren't licensed or regulated like prescription GLP-1 treatments, there's very little evidence to prove whether they can help you lose weight.

There's currently no clinical trial data to support their claims, so it's hard to know if any anecdotal evidence is down to the product or other factors, like lifestyle changes or even the placebo effect.

The other potential issue is the transdermal patch technology that they rely on. It's difficult to know how well the ingredients absorb through the skin, and how strong an effect they can have on the body. Again, without clinical studies, their effects can't be measured or proven.

That's not to say they have no impact at all. But be wary of any that claim to help you burn fat. At best, some of the ingredients may cause mild appetite suppression or temporary water loss, but this is not the same as sustainable weight loss. And often, the ingredients may have been chosen based on research evaluating how effective they are when taken orally, whereas applying them as a patch may produce a different result.

Are weight loss patches safe?

Again, because these products aren’t regulated, it’s hard to say how safe they are. Unlike MHRA-approved medicines, you can't rely on the quality of the ingredients or see the evidence behind the claims.

These alternative treatments are also usually sold online or over the counter, with no clinical assessments in place to check whether they’re right for you and your health history.

If it’s a safe, effective weight loss treatment you’re looking for, you can rest assured that Mounjaro injections are safe, and a licensed medicine that’s proven to support weight loss. [5] And it’s always prescribed by a qualified clinician after a review of your medical history and eligibility check.

It’s also not the only option, so if you’re looking for weight loss support, you can start a consultation and talk to an expert to find out which treatment is best for you.

What are the side effects of weight loss patches?

Depending on the ingredients used in weight loss patches, there may be potential side effects. There's a risk of skin irritation, allergic reactions or even undeclared substances in products sold online. Always check the label and talk to your healthcare provider or GP if you’re unsure, and make sure you discontinue use immediately if you notice any worrying side effects. [6]

Injectable GLP-1 medications also have some side effects. You can find out more about Mounjaro side effects here. [1]

Proven alternatives to weight loss injections

If you’re exploring weight loss patches because you have a phobia of needles or don’t like the idea of injecting yourself weekly, there are other options available that have clinical evidence behind them.

While Mounjaro has to be injected, there are now oral GLP-1 weight loss medications available in the UK.

Wegovy Pill is a daily weight loss tablet that's clinically proven to support meaningful weight loss. It contains semaglutide, which is the same active ingredient used in injectable Wegovy. It works in the same way as injectable GLP-1s, by helping to regulate your appetite, reduce calorie intake and help you feel fuller for longer.

And it’s effective. In a clinical trial, users lost 16.6% of their body weight on average over 64 weeks (1 year, 3 months). It still has to be combined with diet and lifestyle changes, and it has to be taken in a very specific way to work. It's taken once a day, first thing in the morning after 8 hours of fasting. You swallow it with a small amount of plain water (no more than 120ml), and must wait 30 minutes before eating, drinking or taking any other oral medications. [7]

Foundayo is another oral weight loss medication that's due to launch in the UK in summer 2026. It contains orforglipron, a different type of GLP-1. Rather than being peptide-based, orforglipron is a smaller non-peptide molecule that doesn’t get broken down by the digestive system, which is why it can be taken in an oral tablet form. And it can also be taken without the strict routine that you have to follow for the Wegovy Pill. [8]

In clinical trials, users lost an average of 12.4% of their body weight over 72 weeks when taking the highest dose of orforglipron. [9]

It’s also worth knowing that Foundayo is made by Eli Lilly, the same company that makes Mounjaro. However, it’s not ‘oral Mounjaro’, as it contains a very different active ingredient.

What about microneedle patches?

If you’re still interested in alternative treatments, a more promising development could be microneedle patches. These adhesive weight loss patches have small needles in them that pierce the skin barrier, to deliver ingredients directly into the body. Research is still in the early stages, but it's possible that they could be used to deliver weight loss medications. [10]

However, robust phase 3 human trials are needed first to prove their efficacy and safety compared to existing weight loss treatments.

What to do if you’ve bought fake ‘Mounjaro’ or GLP-1 patches

If you have been duped and bought weight loss patches online that claim to contain Mounjaro or other GLP-1 medications, you can report them to the MHRA using its Yellow Card Scheme. The scheme allows you to report any safety issues, including side effects, defective products, and falsified or fake healthcare products. [11]

How to find effective weight loss treatments

A calorie-controlled diet alongside regular physical activity is a good starting point if you're looking to lose weight, but if you need more support, there is help available.

At MedExpress, we offer online consultations with regular clinical check-ins, and a range of weight loss treatments including Mounjaro Pen, Wegovy Pen, Wegovy Pill and Foundayo (coming soon) and our team can help you find the right treatment for you.

References

  1. Mounjaro KwikPen 2.5mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) [Internet]. www.medicines.org.uk. [cited 2026 Aug 3]. Available from: https://www.medicines.org.uk/emc/product/15481/smpc#gref
  2. GOV.UK. GLP-1 medicines for weight loss and diabetes: what you need to know [Internet]. GOV.UK. 2025 June [cited 2026 Aug 3]. Available from: https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know
  3. Khan S, Sharman T. Transdermal Medications [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023 Feb [cited 2026 Aug 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556035/
  4. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. In [cited 2026 Aug 3]. Available from: https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
  5. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine [Internet]. 2022 June 4 [cited 2026 Aug 3];387(3):205–16. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  6. Khan S, Sharman T. Transdermal Medications [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023 Feb [cited 2026 Aug 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556035/
  7. Wharton S, Ildiko Lingvay, Bogdanski P, Duque R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025 Sept 17;393(11):1077–87.
  8. Dutta D, Lakshmi Nagendra, Anne B, Kumar M, Sharma M, A. B. M. Kamrul‐Hasan. Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis. Obesity science & practice [Internet]. 2024 Feb 26 [cited 2026 July 29];10(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896246/
  9. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025 Sept 16;.
  10. Calef Sánchez-Trasviña, Coronel-Meneses D, Aleyda Margarita Escobar-Fernández, Mayolo-Deloisa K. Transdermal microneedle patches as a promising drug delivery system for anti-obesogenic molecules. Frontiers in Bioengineering and Biotechnology [Internet]. 2024 Jun 11;12. Available from: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1380537/full
  11. MHRA. Yellow Card Scheme - MHRA [Internet]. Yellow Card. 2020 [cited 2026 Aug 3]. Available from: https://yellowcard.mhra.gov.uk/

Next scheduled review date: 4 August 2029

Authors

Dr. Zoë Lees, PhD Metabolic Medicine

Written by: Dr. Zoë Lees (PhD)

Dr. Zoë Lees is a medical writer at MedExpress specialising in obesity and health communication. She completed her PhD at the University of Glasgow, where she investigated adipose tissue (fat tissue) function in pregnancies complicated by pre-eclampsia and gestational diabetes. Her work focuses on translating complex clinical evidence into clear, engaging and evidence-based health information for patients and the public. At MedExpress, Zoë contributes to clinical content, educational resources and media communications across areas including weight management, GLP-1 therapies and metabolic disease. Zoë is particularly interested in improving public understanding of obesity as a chronic condition and ensuring patients have access to accurate, accessible health information grounded in current scientific evidence.

Dr. Sophie Dix

Medically reviewed by: Dr. Sophie Dix (BSc, PhD)

Dr. Sophie Dix is Head of Medical Affairs at MedExpress. A behavioural neuroscientist by training, Sophie has spent 30 years working at the intersection of medical research, pharmacology, technology and patient communication across the pharmaceutical industry, health technology and charity sectors. At MedExpress, Sophie's role is to ensure that everything the organisation does is grounded in the most current science. That means translating complex clinical evidence into accessible health information across the website, clinical pathways and media communications. It also means working with external press and broadcast media as a named expert commentator, making the science behind weight management and GLP-1 treatments understandable to a general audience. A core part of Sophie's work is building MedExpress's Real-World Evidence (RWE) programme: learning systematically from patient outcomes to understand what works in practice, not just in clinical trials. This patient-level insight feeds directly into improving patient experience and health outcomes. Sophie believes that patients make better decisions when they have access to accurate, evidence-based information. As an advocate for meaningful change in how obesity is understood, Sophie works to reduce stigma and raise awareness of the condition as an illness. This includes reframing the conversation around GLP-1s from aesthetics to public health, while highlighting the health benefits of weight loss and weight management.

Note from the experts

Remember: This blog shouldn’t be regarded as medical advice, diagnosis, or treatment. We make sure everything we publish is fact checked by clinical experts and regularly reviewed, but it may not always reflect the most recent health guidelines. Always speak to your doctor about any health concerns you have.